StudyGraphics #VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy June 10, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR Ipatasertib plus abiraterone improves survival in PTEN-negative prostate cancer patients compared to abiraterone alone #VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma #VisualAbstract Menopausal hormone therapy was not associated with risk of cutaneous melanoma
